Key Points
- Director Frank Lee sold 24,456 shares of Bausch Health Cos at an average price of $5.43, totaling about $132,796. The sale was made under a pre-arranged Rule 10b5-1 plan and reduced his holdings by 33.14%.
- Bausch Health recently reported Q1 earnings of $0.78 per share, missing estimates by $0.03, even though revenue of $2.46 billion topped expectations. The company also continues to show weak profitability, with negative net margin and very high debt-to-equity.
- Analyst sentiment remains cautious: several firms trimmed price targets or downgraded views, and the stock currently carries an average "Reduce" rating with a consensus target price of $8.00. Institutional ownership remains high, with 78.65% of shares held by institutions.
Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) Director Frank Lee sold 24,456 shares of the firm's stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total value of $132,796.08. Following the completion of the sale, the director directly owned 49,339 shares in the company, valued at approximately $267,910.77. The trade was a 33.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bausch Health Cos Stock Performance
NYSE:BHC opened at $5.51 on Thursday. The company has a quick ratio of 0.97, a current ratio of 1.32 and a debt-to-equity ratio of 54.68. The company has a market cap of $2.06 billion, a P/E ratio of -1.70 and a beta of 0.42. Bausch Health Cos Inc. has a fifty-two week low of $4.41 and a fifty-two week high of $8.69. The firm's 50 day moving average is $5.42 and its two-hundred day moving average is $6.13.
Bausch Health Cos (NYSE:BHC - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing analysts' consensus estimates of $0.81 by ($0.03). The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.37 billion. Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%. Analysts expect that Bausch Health Cos Inc. will post 4.08 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the company. Barclays reduced their price objective on Bausch Health Cos from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 25th. Wall Street Zen lowered Bausch Health Cos from a "strong-buy" rating to a "buy" rating in a research note on Sunday, February 15th. Raymond James Financial reaffirmed a "market perform" rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Royal Bank Of Canada reduced their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a "sector perform" rating on the stock in a research report on Monday, April 27th. Finally, Weiss Ratings cut shares of Bausch Health Cos from a "sell (d)" rating to a "sell (d-)" rating in a research report on Monday, May 4th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Reduce" and a consensus target price of $8.00.
Check Out Our Latest Report on BHC
Key Stories Impacting Bausch Health Cos
Here are the key news stories impacting Bausch Health Cos this week:
- Positive Sentiment: Bausch Health reported the results of its 2026 Annual Meeting, where shareholders elected all 10 director nominees and added Eiry W. Roberts, M.D. to the board, which may support governance and strategic execution. Bausch Health Announces 2026 Annual Meeting of Shareholder Results
- Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $3.93 from $3.92, indicating slightly better near-term profit expectations.
- Neutral Sentiment: The company presented at the RBC Capital Markets Global Healthcare Conference and Barclays’ Leveraged Finance Conference, which kept investor attention on Bausch Health’s strategy and debt profile. Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
- Neutral Sentiment: Director Frank D. Lee sold 24,456 shares under a pre-arranged Rule 10b5-1 plan; while routine, insider selling can still weigh on sentiment. SEC Form 4 filing
- Negative Sentiment: Zacks Research trimmed several forward EPS estimates, including Q2 2027, Q3 2027, Q4 2027, FY2027, Q1 2028 and FY2028, signaling softer long-term earnings expectations.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the stock. Amundi grew its holdings in Bausch Health Cos by 61.7% during the 1st quarter. Amundi now owns 23,983 shares of the company's stock worth $130,000 after acquiring an additional 9,148 shares in the last quarter. Royal Bank of Canada grew its holdings in Bausch Health Cos by 24.9% during the 1st quarter. Royal Bank of Canada now owns 11,363,498 shares of the company's stock worth $61,362,000 after acquiring an additional 2,262,894 shares in the last quarter. Whitebox Advisors LLC grew its holdings in Bausch Health Cos by 3.7% during the 1st quarter. Whitebox Advisors LLC now owns 564,672 shares of the company's stock worth $3,049,000 after acquiring an additional 20,175 shares in the last quarter. Lazard Asset Management LLC grew its holdings in Bausch Health Cos by 15.5% during the 1st quarter. Lazard Asset Management LLC now owns 53,139 shares of the company's stock worth $287,000 after acquiring an additional 7,114 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Bausch Health Cos by 10.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,575,772 shares of the company's stock worth $8,509,000 after acquiring an additional 143,581 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors.
About Bausch Health Cos
(
Get Free Report)
Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.
The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
